Latest Content

Employers struggle to define value from health care spending amid complexity and misaligned incentives. Achieving measurable outcomes requires transparency, incentive realignment, and gradual, employee-centered change.

A large review identifies 70 safety signals for bimekizumab, confirming known risks while revealing previously unreported adverse events.

Semaglutide, sotatercept, and bentracimab trials were attendees’ main focus at the American College of Cardiology 2025 Annual Scientific Session.

Artificial intelligence and lung cancer highlighted the top conference coverage from the Association of Cancer Care Centers Annual Meeting in Washington, DC.

Inebilizumab gains FDA approval for treating generalized myasthenia gravis, showing significant improvements in muscle strength and steroid reduction.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Five key oncology FDA approvals came through last month, expanding treatment options across multiple cancer types.

The oral medication could be used in gonorrhea that is resistant to antibiotics according to a new phase 3 clinical trial.

The novel biomarker APP performed comparably to Fibrosis-4 overall and showed improved cirrhosis detection in patients with diabetes.